BOW Group Acquires Musart, Adding Innovative Art Marketplace to Its Offering
29.7.2021 16:15:00 EEST | Business Wire | Press release
BOW Group today announced that it has successfully completed the acquisition of Musart.com, a fast-growing online destination to buy original artworks and licensed products. This transaction will allow BOW Group to seize new opportunities in the booming digital art market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005637/en/
(Photo: Musart)
“BOW Group and Musart share the same passion for good yet accessible design that brings emotions to consumers at every moment of the day,” said Boris Brault, BOW Group Founder and CEO. “Together, with Musart’s unique product curation and established relationships with leading institutions, we can conquer the thriving online art market thanks to our global ecommerce, logistics and development capabilities. With Musart in our portfolio, we are expanding our offering and enhancing the growth potential of our business beyond IoT and lifestyle objects. Today, the art world is fundamentally changing, disrupted with new players and media; we want to participate in that shift by helping consumers get access to art pieces and accessories, under different forms, at every price points.”
Since its inception in 2014, Musart has sold thousands of pieces of collectibles. Founded by French Art-Lover and Entrepreneur Vincent Gregoire, Musart’s mission is to make art accessible, giving anyone the opportunity to «own a piece of museum».
Partnerships with world-class museums, foundations and cultural organizations allow Musart to bring not only exclusive and authentic items, but also, to honor iconic artists such as Basquiat, Cattelan, Da Vinci, Dali, Haring, Hokusai, Kahlo, Klimt, Kusama, Magritte, Michelangelo, Miró, Modigliani, Mondrian, Picasso, Pollock, Van Gogh, Warhol. Licensed items, numbered and signed pieces include the world famous Kaws, Medicom Toy Be@rbricks and Kidrobot, as well as new promising talents. The selection spans multiple product categories: sculptures, home decor and office accessories, stationary, books, clothing, etc... with prices ranging from $20 to $20,000.
Customers receive not only an art piece but also a short biography of the corresponding artist for each purchase, proving Musart’s commitment to democratizing art and its educative vocation. Headquartered in Miami, Musart has first experienced a retail journey and embarked into a successful digital experience with its own website and 5-stars Central Seller page on Amazon, gathering today more than 1000 references and a highly active community of collectors.
By joining BOW Group, Musart will benefit from the group’s 360° platform, including a mature D2C digital ecosystem, multiple warehouse locations to serve consumers around the globe and its R&D center BOW Industries to handle its licensed and private label activities. One of the first objectives is to expand Musart’s sales activity outside the US, especially in Europe. While Musart will undoubtedly diversify BOW Group’s offering from a B2C standpoint, it will also meet the demand of B2B and Corporate customers with a whole new range of exciting gift objects.
Musart Founder Vincent Gregoire said: “I’m thrilled to join BOW Group with whom we share the same entrepreneurial mindset and consumer-driven approach. This integration marks a new chapter for Musart, one that will definitely help us reach our full potential at a global scale and embrace the new disruptive changes of our industry, such as NFTs. Leveraging BOW’s existing digital resources, ecommerce and supply chain infrastructure will take our business to another level, bringing innovative online experiences such as AR technology while continuing to make art accessible to anyone.”
Follow Musart
Instagram: https://www.instagram.com/musartboutique/
Facebook: https://www.facebook.com/musartboutique/
About BOW Group
BOW Group is a global player and multi-skilled platform operating worldwide with two consumer brands: Lexon, the design object editor, and MyKronoz, the IoT specialist - both powered by its own R&D and manufacturing center, BOW Industries. In addition, BOW Group owns the luxury concept-store chain Legacy.
Every year, BOW Group sells about 2 million pieces of products in 90 countries and across 9000 points of sales, thanks to its international recognition and network of leading designers celebrated with more than 200 Awards received, including 7 Red Dot Design Awards won by its two brands in 2021.
BOW Group has now more than 100 talents spread across four office locations: Paris, Geneva, Miami and Shenzhen.
Since July 2015, BOW has opened up its capital to NextStage AM, then, in 2017 to PM Equity Partner - the corporate venture fund of Philip Morris International.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005637/en/
Contact information
Annabel Corlay
a.corlay@group-bow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom